Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
11 July 2024 - 8:30PM
UK Regulatory
Zymeworks To Report Second Quarter 2024 Financial Results
and Host Conference Call on August 1, 2024
VANCOUVER, British Columbia, July 11, 2024 (GLOBE
NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage
biotechnology company developing a diverse pipeline of novel,
multifunctional biotherapeutics to improve the standard of care for
difficult-to-treat diseases, today announced that management will
report its second quarter 2024 financial results after market close
on August 1, 2024. Following the announcement, management will host
a conference call and webcast to discuss financial results and
provide a corporate update on August 1, 2024 at 4:30 pm
Eastern Time (ET).
The event will be webcast live with dial-in details and webcast
replays available on Zymeworks’ website
at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks’ mission is to
make a meaningful difference in the lives of people impacted by
difficult-to-treat cancers and other diseases. The Company’s
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using the
Company’s proprietary Azymetric™ technology. Zymeworks has entered
into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each exclusive
rights to develop and commercialize zanidatamab in different
territories. Zanidatamab is currently being evaluated in multiple
global clinical trials as a potential best-in-class treatment for
patients with HER2-expressing cancers. A Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA)
seeking accelerated approval for zanidatamab as a treatment for
previously-treated, unresectable, locally advanced, or metastatic
HER2-positive biliary tract cancer (BTC) has been accepted and
granted Priority Review. A BLA has also been accepted for review by
the Center for Drug Evaluation (CDE) of the National Medical
Products Administration (NMPA) in China. If approved, zanidatamab
would be the first HER2-targeted treatment specifically approved
for BTC in the U.S. and China. Zymeworks is rapidly advancing a
deep pipeline of product candidates based on its experience and
capabilities in both antibody-drug conjugates and multispecific
antibody therapeutics across multiple novel targets in indications
that represent areas of significant unmet medical need. In addition
to Zymeworks’ wholly owned pipeline, its therapeutic platforms have
been further leveraged through strategic partnerships with global
biopharmaceutical companies. For information about Zymeworks, visit
www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
investors@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
ir@zymeworks.com
media@zymeworks.com
Zymeworks BC (TG:ZA8)
Historical Stock Chart
From Dec 2024 to Jan 2025
Zymeworks BC (TG:ZA8)
Historical Stock Chart
From Jan 2024 to Jan 2025
